Pharmacoeconomic impact of empagliflozin in patients with chronic kidney disease
Background. Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of renal failure in patients with chronic kidney disease (CKD). Objective. To evaluate the pharmacoeconomic impact of empagliflozin in patients with CKD. Material and methods. The economic impact of empagliflozin...